Drug Approval | November 19, 2024
Shilpa Pharma Lifesciences received CEP from EDQM for API, Octreotide
Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis
Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis
Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters
Launch of new product range aligns with strategy to diversify into emerging applications with high growth potential
Univar Solutions' pharmaceutical ingredients portfolio will be strengthened by the addition of a broad range of cellulose ethers and other excipient solutions
This agreement reinforces Lubrizol’s commitment to Make-In-India and broadens a previously committed US$ 350 million investment to support local manufacturing
Construction of the plant will commence in 2025 with first production expected to be in 2027
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
_256_384.jpg)
Tyvek with Renewable Attribution is designed to help reduce the carbon footprint
Subscribe To Our Newsletter & Stay Updated
